Tanabe Pharma
Shionogi Announces $2.5 Billion Acquisition of ALS Drug Radicava from Tanabe Pharma
Shionogi; Tanabe Pharma; Radicava; ALS; acquisition; $2.5B; rare disease
Mitsubishi Tanabe and Dewpoint Therapeutics Collaborate on $480M ALS Treatment Development
ALS treatment, Dewpoint Therapeutics, Mitsubishi Tanabe Pharma Corporation, TDP-43, small molecule condensate modulator, biobucks deal